Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 86 Long-acting obesity compounds in phase 1 development may have complimentary modes of action Key features of compounds in phase 1 development for obesity Compound G530S - Glucagon analogue NN9838-Amylin analogue NN9747 PYY analogue Once-daily subcutaneous Administration injection in combination with liraglutide Mode of action Clinical development status • • Stimulation of energy expenditure and satiety promoting a negative energy balance Phase 1 initiated Sep 2014 Safety/PK of single ascending doses 160 overweight/obese people Expected completion 2017 • • Once-daily subcutaneous injection Reduced food intake, thought primarily to be mediated by amylin receptors located in the area postrema Phase 1 initiated Dec 2014 Safety/PK of single and multiple ascending doses 140 overweight/obese people Expected completion 2018 Once-daily subcutaneous injection Reduced food intake via selective stimulation of the Y2 receptor Phase 1 initiated Oct 2015 Safety/PK of single and multiple doses 120 overweight/obese people Expected completion 2019 PK: pharmacokinetic changing diabetes novo nordisk

View entire presentation